Stock Alert: Calithera (CALA) Trades 10.37% Lower June 21

Equities Staff  |

Calithera Biosciences Inc (NASDAQ:CALA) stock was among today's market movers, ending trading down 10.37% to $2.42 on June 21.

264,653 shares exchanged hands in comparison to the 30-day daily average of 178,496 shares.

The company's stock has moved 79.71% so far in 2022.

Calithera shares have fluctuated between $2.31 and $49.80 over the past twelve months.

For technical charts, analysis, and more on Calithera visit the company profile.

About Calithera Biosciences Inc

Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California.

To get more information on Calithera Biosciences Inc and to follow the company's latest updates, you can visit the company's profile page here: Calithera Biosciences Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content